BMO Capital analyst Evan Seigerman has maintained their neutral stance on NBIX stock, giving a Hold rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Evan Seigerman has given his Hold rating due to a combination of factors that highlight potential headwinds for Neurocrine’s growth prospects. The company’s flagship drug, Ingrezza, showed signs of slowing growth with a lower-than-expected sales guidance for 2025, falling short of market consensus by around 5%. This underperformance, paired with lighter-than-anticipated sales for the current quarter, suggests that the incremental benefits from past investments in sales and marketing are tapering off.
Additionally, the early sales figures for Crenessity, although somewhat promising, do not yet provide a strong foothold to offset the challenges faced by Ingrezza. As Neurocrine shifts its focus towards diversifying its pipeline and investing more in new products like Crenessity, the short-term outlook remains uncertain without immediate catalysts. Consequently, Seigerman’s Hold rating reflects a cautious stance as the company navigates these transitional phases and seeks to stabilize its commercial performance.
Seigerman covers the Healthcare sector, focusing on stocks such as Amgen, Merck & Company, and Novo Nordisk. According to TipRanks, Seigerman has an average return of 7.2% and a 48.97% success rate on recommended stocks.